When compared to other methylation biomarkers in stool-based tests, the sensitivities of methylated C9orf50 and methylated KCNQ5 for all stage CRC detection, 85.9 and 77.3% respectively, fell within the range of other markers from 71.2% for methylated HPP1 (55) to 92.5% for methylated COL4A2 (33). This evidence concerns the gene KCNQ5 and colorectal carcinoma.